Get the app
US › Healthcare

Coherus BioSciences Inc (CHRS)

US · Healthcare · Biotechnology

$0.99-7.48%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$14.3M
Revenue YoY
+39.5%
Net profit
$-20.6M
EPS
$-0.22
EPS estimate
$-0.16
Net margin
-144.2%

EPS came in at -0.22 against a street estimate of -0.16 — a miss of 37.5%.

Key statistics

Market cap
$165.3M
Forward P/E
41.2
P/B
3.19
Book value
$0.39
EPS (TTM)
$-1.25
52-week high
$2.62
52-week low
$0.97
50-day MA
$1.28
200-day MA
$1.56
Beta
0.99

Analyst view

Analysts rate Coherus BioSciences Inc a strong buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $7.75.

Shareholding

Insiders
19.12%
Institutions
37.46%

Largest institutional holders

FundStake
Timothy G. Youngquist 2020 Irrevocable Trust8.45%
BlackRock Inc7.77%
Vanguard Capital Management, LLC3.85%
Geode Capital Management, LLC2.39%
Samsara BioCapital, LLC2.22%
Kohlberg Kravis Roberts & Co LP1.97%
State Street Corp1.54%
Two Sigma Investments LLC1.46%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Coherus BioSciences Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.